San Diego

In our latest ASH analysis, we’re going to focus on some key early stage oncology developments and their associated emerging strategic themes to watch out for.

After all, looking to see what’s coming behind you can be just as important as what’s in front of you.

In this latest review, we highlight and discuss 14 abstracts from a mix of pharma and biotech companies based across several continents, with various intriguing developments spanning preclinical to phase 2 involving a mix of targets and modalities…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by